These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 18633214)

  • 1. [Intraperitoneal chemotherapy for ovarian cancer].
    Noma J; Yoshida N
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
    Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
    Fiorentini G; Filippeschi M; Turrisi G; Mambrini A; Giannessi PG; D'Alessandro M; Rossi S; Dentico P; Guadagni S; Cantore M; Madrigali A
    In Vivo; 2009; 23(2):317-21. PubMed ID: 19414421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer.
    Markman M
    Semin Oncol; 2006 Dec; 33(6 Suppl 12):S3-7. PubMed ID: 17223444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.
    Vergote I; Amant F; Leunen K; Cadron I; Van Gorp T; Neven P; Berteloot P
    Oncologist; 2008 Apr; 13(4):410-4. PubMed ID: 18448555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
    Tummala MK; Alagarsamy S; McGuire WP
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1135-47. PubMed ID: 18588458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Controversies regarding intraperitoneal chemotherapy for advanced ovarian cancer].
    Miron L; Onofriescu M; Marinca M
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(3):583-9. PubMed ID: 20201236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 13. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer.
    Fujiwara K; Nagao S; Aotani E; Hasegawa K
    Expert Opin Pharmacother; 2013 Sep; 14(13):1797-806. PubMed ID: 23915009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.
    Almadrones L
    Clin J Oncol Nurs; 2007 Apr; 11(2):211-6. PubMed ID: 17573270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intraperitoneal chemotherapy in ovarian carcinoma].
    Piura B
    Harefuah; 2001 Sep; 140(9):844-9, 894, 893. PubMed ID: 11579736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ovarian cancer -- can peritoneal therapy be regarded as new standard?].
    du Bois A; Schmalfeldt B; Meier W; Sehouli J; Pfisterer J
    Zentralbl Gynakol; 2006 Aug; 128(4):202-6. PubMed ID: 16835814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of epithelial ovarian cancer.
    Bhoola S; Hoskins WJ
    Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intraperitoneal chemotherapy in first-line combination treatment for advanced ovarian cancer].
    Massard C; Lhommé C; Pautier P
    Bull Cancer; 2007 Apr; 94(4):398-404. PubMed ID: 17449443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
    Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
    Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.